Should You Buy SpaceX Stock Before Its Next Earnings Report?

SpaceX shares rebounded to roughly $155 after trading between an approximately $226 high and $105 low following its $135 IPO, as investors weigh AI-growth optimism against substantial spending and valuation risk. The company reported $7.8 billion of revenue, up 92%, with AI revenue nearly tripling to $2.6 billion, while management targets a $100 billion annual recurring revenue run rate by year-end. However, first-quarter AI capex was $7.7 billion and the segment posted a $2.5 billion operating loss, leaving November earnings focused on whether cloud-contract revenue can scale fast enough to justify infrastructure costs and a roughly $2 trillion market capitalization.

Analysis

The investable issue is not whether SPCX can report rapid top-line growth, but whether purported compute contracts convert into multi-year, take-or-pay revenue at returns above the cost of GPU, networking, power, and launch-related capital. A $100B run-rate narrative supports a premium infrastructure multiple only if customer concentration, cancellation provisions, and depreciation-normalized free-cash-flow conversion are disclosed; otherwise, the equity is effectively underwriting an externally financed AI buildout. The stated scale of capex implies that even a strong November revenue print could be accompanied by worsening cash burn and a higher required return on incremental capital.

Near term, the combination of limited trading float and upcoming unlocks creates a mechanically asymmetric setup: incremental supply can overwhelm a narrative-driven shareholder base regardless of operating momentum. The relevant 1-3 month catalyst is not subscriber or launch volume but contracted backlog, prepayments, capex guidance, and the ratio of AI revenue to deployed infrastructure. A miss on any one of these measures would likely compress the valuation multiple before it materially changes reported revenue.

The non-obvious competitive implication is that aggressive capacity leasing can tighten high-end accelerator, optical-networking, and power-equipment availability, supporting NVDA and selected infrastructure vendors even if SPCX equity derates. Conversely, buying distressed AI-startup assets is not automatically an input-cost advantage: used GPUs may be technologically mismatched, while customer data can carry integration, privacy, and chain-of-title risk. Consensus appears too willing to treat announced or rumored contracts as equivalent to durable ARR; the more valuable signal is whether counterparties commit capital upfront and renew after initial inference workloads are deployed.

Key Decisions for Investors

• Avoid initiating a directional SPCX long ahead of November unless filings verify contract duration, termination rights, customer concentration, and cash prepayments. Reassess after results if AI capex growth decelerates below revenue growth while contracted backlog expands; that combination would support a 6-18 month long thesis.
• For a tactical 1-3 month expression, consider long NVDA versus short SPCX in equal beta-adjusted dollars, targeting a 10-15% relative move. The pair captures continued AI hardware scarcity while hedging the risk that SPCX's equity multiple compresses on cash-flow or unlock concerns; exit if SPCX demonstrates material prepaid, multi-year backlog and credible capex discipline.
• Establish an alert around SPCX lockup-expiry dates and implied volatility. If post-earnings implied volatility remains elevated but verified guidance is unchanged, a defined-risk put spread dated beyond the first major unlock may offer better asymmetry than short stock; do not execute without current option open interest and borrow-cost data.
• Treat DB's favorable framing as sentiment rather than a standalone catalyst. Monitor whether formal underwriting, financing commitments, or revised estimates emerge; absent those, there is no actionable DB trade from the coverage signal alone.